GLP-1s and birth control
Last updated: October 2, 2026 · 4 min read · By the Grey Peptides Editorial Board
- Tirzepatide's labels (Zepbound and Mounjaro) warn that it may make birth control pills less effective, because it slows how fast the stomach empties.
- Both labels advise switching to a non-oral method, or adding a barrier method such as condoms, for 4 weeks after starting and for 4 weeks after every dose increase. IUDs, implants and other non-oral hormonal methods should not be affected.
- The 'Ozempic babies' stories are anecdotal, with two plausible causes: weight loss can restore fertility, and the pill can be less reliable on tirzepatide. These drugs are not used in pregnancy, so pregnancy should be planned with a prescriber.
What the label says
The warning is written into the prescribing information. The labels for Zepbound and Mounjaro, the two brands of tirzepatide High, both say that tirzepatide may reduce the efficacy of oral hormonal contraceptives because it delays gastric emptying 1 2. They advise patients using oral contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after starting treatment and for 4 weeks after each dose escalation 1 2. Hormonal contraceptives that are not taken by mouth should not be affected 1.
Because tirzepatide is started at a low dose and raised in steps, those 4-week windows recur several times during the first months of treatment, which is when the advice matters most.
Why: a slower stomach
Tirzepatide slows the passage of food, and anything swallowed with it, out of the stomach. A pill that depends on being absorbed on time can then reach the bloodstream later and at a lower peak. The only pharmacokinetic study, summarised in a 2026 review, gave a single 5 mg dose of tirzepatide with a combined oral contraceptive and found peak blood levels of ethinylestradiol and norgestimate fell by 59% and 66% 3. The fall for norgestimate's active metabolite was much smaller, and the review's authors stress that a lower peak cannot be equated with reduced contraceptive efficacy 3. No study has measured pregnancy rates on the pill during tirzepatide treatment; the label advice is a precaution based on the absorption data.
What about semaglutide?
Semaglutide High also slows the stomach, but its label is different. The Wegovy label we read lists an oral contraceptive among the drugs studied with semaglutide at steady state and carries no instruction to switch or add contraception 4. That is the label position, not a guarantee; anyone relying on the pill while starting any GLP-1 drug can ask their prescriber whether a backup method makes sense, especially while doses are rising.
The 'Ozempic babies' reports
Social media and news outlets have carried many stories of unexpected pregnancies in women taking these drugs, nicknamed "Ozempic babies" 5. They are reports, not a measured rate, but there are two plausible explanations. Weight loss itself can restore fertility: in trials of weight-loss programmes, losses averaging about 7% led to more spontaneous conceptions 5. And for tirzepatide, the pill may be less reliable, as its label warns 1.
The trend is growing with use. A 2025 review in Clinical Science notes that the number of young women in the US using GLP-1 drugs rose 659% between 2020 and 2023 6. These drugs are not licensed for use in pregnancy; animal studies suggest effects on fetal growth, while the early human case reports from unplanned pregnancies have not shown harm, a body of evidence that is still small 6. The UK's MHRA advises women taking these medicines to use effective contraception, and in some cases to keep using it for up to two months after stopping before trying to conceive 7.
What to do
If you take the pill and are starting tirzepatide, the labels give the plan: switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase 1. Methods not taken by mouth, such as an IUD, an implant, a patch or a ring, should not be affected 1. If you are planning a pregnancy, discuss timing with your prescriber before stopping contraception, including how long to stop the drug beforehand 7.
Frequently asked questions
Does tirzepatide affect birth control?
Its labels say it may make oral contraceptives less effective, because it slows stomach emptying. They advise a non-oral method or a barrier backup for 4 weeks after starting and after each dose increase.
Does Ozempic or Wegovy affect birth control?
The Wegovy label we read carries no instruction to change contraception; it lists an oral contraceptive among drugs studied with semaglutide. Ask your prescriber about a backup method while doses rise.
What are Ozempic babies?
Unplanned pregnancies reported by women on GLP-1 drugs. They are anecdotal; weight loss restoring fertility and, for tirzepatide, a less reliable pill are the likely explanations.
Which birth control is not affected?
The tirzepatide labels say hormonal contraceptives not taken by mouth, such as implants, IUDs, patches and rings, should not be affected.
Related on Grey Peptides
Sources
- Zepbound (tirzepatide) US prescribing information, openFDA label set 487cd7e7-434c-4925-99fa-aa80b1cc776b, effective August 28, 2026; read October 2, 2026.
- Mounjaro (tirzepatide) US prescribing information, openFDA label set 0818426a-53eb-4db7-9609-bbae1e7a3964, effective July 29, 2026; read October 2, 2026.
- Viana, D. P. D. C., Invitti, A. L., Jacobsen, L., et al. (2026). Tirzepatide and oral progestogens: A hypothesis-generating review of a biologically plausible pharmacokinetic interaction in gynaecologic disease control and menopausal hormone therapy. Maturitas, 214, 109116. PMID: 42721915
- Wegovy (semaglutide) US prescribing information, openFDA label set f5e548d0-cc79-4c34-a3f5-e20a5b8b6564, effective April 23, 2024; read October 2, 2026.
- Pharmacy Times. So-called 'Ozempic babies' raise questions about unintended effects of GLP-1 agonists (pharmacytimes.com), 2026; read October 2, 2026.
- Incretin receptor agonism during pregnancy: implications for mother and baby. Clinical Science, 139(23), 1597 (2025); read October 2, 2026.
- Medicines and Healthcare products Regulatory Agency (UK). Guidance on GLP-1 medicines, contraception and pregnancy, as reported in UK national news coverage; read October 2, 2026.
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead